53 Participants Needed

Markers for Primary Immunodeficiency

Recruiting at 5 trial locations
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Meyer Children's Hospital IRCCS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.

What data supports the effectiveness of the treatment for identifying specific markers in primary immunodeficiency?

Research suggests that understanding the genetic basis and using biologic response modifiers (substances that modify immune responses) can improve the treatment of primary immunodeficiency disorders. Advances in identifying genetic defects and immune system regulation have led to better therapies, such as subcutaneous immunoglobulin infusions, which have shown positive results in managing these conditions.12345

What safety data exists for the treatment related to markers for primary immunodeficiency?

The research articles provided do not contain specific safety data for treatments related to markers for primary immunodeficiency.56789

How does the treatment for identifying markers in primary immunodeficiency differ from other treatments?

This treatment is unique because it focuses on identifying specific markers on immune cells using monoclonal antibodies, which helps in diagnosing and classifying different types of primary immunodeficiencies, rather than directly treating the condition itself.1011121314

What is the purpose of this trial?

Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies

Eligibility Criteria

This trial is for patients with autoimmune cytopenias, which include conditions like low platelet count, anemia, and low white blood cell count that are resistant to treatment. These patients may also have primary immunodeficiencies (PI).

Inclusion Criteria

For immune thrombocytopenic purpura: platelet count increase >30,000 with at least a twofold increase from pre-treatment value
I have been diagnosed with a blood disorder where my immune system attacks my blood cells.
For autoimmune hemolytic anemia: Hb ≥10 g/dL with an increase of at least 2 g/dL compared to baseline

Exclusion Criteria

I have a temporary low blood cell count without autoimmune disease, not needing immediate treatment.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Identification of specific markers

Analysis of the immunological profile, genetic analysis using next-generation sequencing (NGS) technology, bioinformatic analysis, and functional studies

Every three to six months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Identification of specific markers
Trial Overview The study aims to identify specific early biomarkers in the immune system that can help diagnose autoimmune cytopenias and predict who will respond well to therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Identification of specific markersExperimental Treatment1 Intervention
Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Meyer Children's Hospital IRCCS

Lead Sponsor

Trials
62
Recruited
17,500+

References

Biologic response modifiers in primary immunodeficiency disorders. [2019]
Primary immunodeficiency disorders. [2019]
[When should immunologic explorations be carried out in children with suspicion of primary immunodeficiency?]. [2013]
Immunodeficient states and associated rheumatic manifestations. [2019]
Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. [2022]
The European internet-based patient and research database for primary immunodeficiencies: results 2004-06. [2022]
Laboratory screening for the diagnosis of children with primary immunodeficiencies. [2013]
Diagnostic and Predictive Contribution of Autoantibodies Screening in a Large Series of Patients With Primary Immunodeficiencies. [2021]
NEWBORN SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCIES USING TRECS AND KRECS: SECOND PILOT STUDY IN BRAZIL. [2022]
T-cell subset analysis by monoclonal antibodies in primary immunodeficiencies. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Flow cytometry assays in primary immunodeficiency diseases. [2010]
Monoclonal antibody analysis of T cell subsets in 40 patients with immunodeficiencies. [2007]
13.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Membrane markers of T- and B-lymphocytes in children with primary immunologic deficiency conditions]. [2016]
14.United Statespubmed.ncbi.nlm.nih.gov
Lymphocytes in patients with variable immunodeficiency and panhypogammaglobulinemia. Evaluation of B and T cell surface markers and a proposed classification. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security